{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:07Z","timestamp":1786985407031,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.blre.2020.100716","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T19:37:30Z","timestamp":1590867450000},"page":"100716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Management of challenging myelofibrosis after JAK inhibitor failure and\/or progression"],"prefix":"10.1016","volume":"42","author":[{"given":"Robyn M.","family":"Scherber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.blre.2020.100716_bb0005","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/leu.2008.229","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science","volume":"22","author":"Kilpivaara","year":"2008","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100716_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100716_bb0015","author":"Network"},{"key":"10.1016\/j.blre.2020.100716_bb0020","author":"Federal Drug Administration"},{"issue":"21","key":"10.1016\/j.blre.2020.100716_bb0025","first-page":"2820","article-title":"A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of Ruxolitinib for the treatment of myelofibrosis","volume":"122","author":"Hagop","year":"2013","journal-title":"BLood."},{"issue":"8","key":"10.1016\/j.blre.2020.100716_bb0030","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2020.100716_bb0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.blre.2020.100716_bb0040","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2020.100716_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-018-0095-2","article-title":"Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis","volume":"8","author":"Mudireddy","year":"2018","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.blre.2020.100716_bb0050","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2020.100716_bb0055","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100716_bb0060","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2020.100716_bb0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"BLood."},{"issue":"9","key":"10.1016\/j.blre.2020.100716_bb0070","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood."},{"issue":"21","key":"10.1016\/j.blre.2020.100716_bb0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: An AGIMM & IWG-MRT project","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100716_bb0080","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.blre.2020.100716_bb0085","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V124.21.406.406","article-title":"Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2020.100716_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.blre.2020.100716_bb0095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ajh.24881","article-title":"Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.blre.2020.100716_bb0100","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1016\/j.clml.2017.07.179","article-title":"Do we need to re-define accelerated phase of myelofibrosis? Correlation between blast percentage in myelofibrosis and outcomes","volume":"17","author":"Masarova","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"14","key":"10.1016\/j.blre.2020.100716_bb0105","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"BLood."},{"issue":"10","key":"10.1016\/j.blre.2020.100716_bb0110","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.blre.2020.100716_bb0115","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"BLood."},{"issue":"5","key":"10.1016\/j.blre.2020.100716_bb0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.blre.2020.100716_bb0125","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.blre.2020.100716_bb0130","first-page":"A4197","article-title":"Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib","volume":"634","author":"Harrison","year":"2017","journal-title":"ASH"},{"key":"10.1016\/j.blre.2020.100716_bb0135","author":"Celegene Press Release"},{"issue":"7","key":"10.1016\/j.blre.2020.100716_bb0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood."},{"issue":"21","key":"10.1016\/j.blre.2020.100716_bb0145","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.blre.2020.100716_bb0150","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100716_bb0155","article-title":"Erythropoiesis stimulating agents can improve Anemia in patients with myelofibrosis treated with Ruxolitinib","volume":"181108","author":"Crisna","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100716_bb0160","first-page":"a199","article-title":"Flu\/Mel conditioning long term alloSCT outcomes in MF","volume":"130","author":"Ali","year":"2017","journal-title":"Blood."},{"issue":"S1","key":"10.1016\/j.blre.2020.100716_bb0165","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2018-99-114125","article-title":"Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: initial results of a phase II study","volume":"132","author":"Rampal","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100716_bb0170","article-title":"Ruxolitinib plus pomalidomide in myelofibrosis with anemia: results from the MPNSG-0212 combination trial (NCT01644110)","volume":"S1608","author":"Stegelmann","year":"2019","journal-title":"Haematologica."},{"issue":"22","key":"10.1016\/j.blre.2020.100716_bb0175","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: eastern cooperative oncology group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"BLood."},{"issue":"8","key":"10.1016\/j.blre.2020.100716_bb0180","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/j.blre.2020.100716_bb0185","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/leu.2008.91","article-title":"A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"22","author":"Quintas-Cardama","year":"2008","journal-title":"Leukemia."},{"issue":"33","key":"10.1016\/j.blre.2020.100716_bb0190","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.blre.2020.100716_bb0195","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.29753","article-title":"Comprehensively understanding fatigue in patients with myeloproliferative neoplasms","volume":"122","author":"Scherber","year":"2016","journal-title":"Cancer."},{"issue":"6","key":"10.1016\/j.blre.2020.100716_bb0200","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12185-013-1353-5","article-title":"Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms","volume":"97","author":"Bhagwat","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.blre.2020.100716_bb0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1054\/blre.1999.0110","article-title":"Splenic irradiation in myelofibrosis with myeloid metaplasia: a review","volume":"13","author":"Elliott","year":"1999","journal-title":"Blood Rev."},{"issue":"34","key":"10.1016\/j.blre.2020.100716_bb0210","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.blre.2020.100716_bb0215","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.blre.2020.100716_bb0220","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.blre.2020.100716_bb0225","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2020.100716_bb0230","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.blre.2020.100716_bb0235","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.blre.2020.100716_bb0240","author":"ClinicalTrials.gov"},{"issue":"6","key":"10.1016\/j.blre.2020.100716_bb0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.blre.2020.100716_bb0250","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.blre.2020.100716_bb0255","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.blre.2020.100716_bb0260","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100716_bb0265","first-page":"485645","article-title":"Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms","volume":"2014","author":"Wang","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"15","key":"10.1016\/j.blre.2020.100716_bb0270","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1200\/JCO.2017.35.15_suppl.7063","article-title":"Phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis","volume":"35","author":"Masarova","year":"2017","journal-title":"JCO."},{"issue":"5","key":"10.1016\/j.blre.2020.100716_bb0275","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjh.13046","article-title":"Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms","volume":"167","author":"Mwirigi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2020.100716_bb0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.11.015","article-title":"A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera\/essential thrombocythemia myelofibrosis (post-PV\/ET MF)","volume":"53","author":"Mascarenhas","year":"2017","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.blre.2020.100716_bb0285","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.blre.2020.100716_bb0290","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2018-99-110595","article-title":"Ivosidenib (AG-120) induced durable remissions and transfusion Independence in patients with IDH1-mutant untreated AML: results from a phase 1 dose escalation and expansion study","volume":"132","author":"Roboz","year":"2018","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2020.100716_bb0295","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA approval summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an Isocitrate Dehydrogenase-1 mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.blre.2020.100716_bb0300","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2020.100716_bb0305","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLML.2010.n.059","article-title":"Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis","volume":"10","author":"Parikh","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"10.1016\/j.blre.2020.100716_bb0310","article-title":"Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML)","volume":"35","author":"Medeiros","year":"2017","journal-title":"JCO."},{"issue":"1","key":"10.1016\/j.blre.2020.100716_bb0315","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2013.042","article-title":"Acute panmyelosis with myelofibrosis - a rare subtype of acute myeloid leukemia","volume":"5","author":"Chatterjee","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"8","key":"10.1016\/j.blre.2020.100716_bb0320","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.blre.2020.100716_bb0325","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V128.22.4276.4276","article-title":"The cytotoxic effect of the PARP inhibitor ABT-888 on myeloproliferative neoplasms","volume":"128","author":"Patel","year":"2016","journal-title":"Blood."},{"issue":"S1","key":"10.1016\/j.blre.2020.100716_bb0330","first-page":"1631","article-title":"A multicenter, open-label, pilot study of alisertib (MLN8237), a novel inhibitor of Aurora kinase a, in myelofibrosis","volume":"130","author":"Gangat","year":"2017","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2020.100716_bb0335","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia."},{"issue":"S1","key":"10.1016\/j.blre.2020.100716_bb0340","first-page":"258","article-title":"Phase I\/II trial of Glasdegib in heavily pre-treated patients with primary or secondary myelofibrosis","volume":"130","author":"Gerds","year":"2017","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2020.100716_bb0345","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor Imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"S1","key":"10.1016\/j.blre.2020.100716_bb0350","first-page":"256","article-title":"Interim phase 2 clinical trial results for LCL161, an Oral Smac mimetic, in patients with intermediate or high risk myelofibrosis","volume":"130","author":"Pemmaraju","year":"2017","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.blre.2020.100716_bb0355","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood.V128.22.1963.1963","article-title":"HSP27: a therapeutic target in myelofibrosis","volume":"128","author":"Sevin","year":"2016","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.blre.2020.100716_bb0360","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood.V128.22.3108.3108","volume":"128","author":"Drexler","year":"2016","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.blre.2020.100716_bb0365","first-page":"4179","article-title":"Phase 1b results of a study to assess the efficacy and safety of Vismodegib in combination with Ruxolitinib in patients with intermediate- or high-risk myelofibrosis","volume":"130","author":"Couban","year":"2017","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2020.100716_bb0370","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V126.23.56.56","article-title":"PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks","volume":"126","author":"Verstovsek","year":"2015","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2020.100716_bb0375","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quintas-Cardama","year":"2012","journal-title":"Blood."},{"issue":"S1","key":"10.1016\/j.blre.2020.100716_bb0380","first-page":"2908","article-title":"Results from ongoing phase 1\/2 trial of SL-401 in patients with myeloproliferative neoplasms including chronic Myelomonocytic leukemia and primary myelofibrosis","volume":"130","author":"Patnaik","year":"2017","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2020.100716_bb0385","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood.V126.23.825.825","article-title":"Phase 1b\/2 study of the efficacy and safety of Sonidegib (LDE225) in combination with Ruxolitinib (INC424) in patients with myelofibrosis","volume":"126","author":"Gupta","year":"2015","journal-title":"Blood."},{"issue":"S1","key":"10.1016\/j.blre.2020.100716_bb0390","first-page":"255","article-title":"Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia","volume":"130","author":"Prithviraj Bose","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2020.100716_bb0395","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.V126.23.827.827","article-title":"An open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of Ruxolitinib and Buparlisib (BKM120) in patients with myelofibrosis: results from HARMONY study","volume":"126","author":"Durrant","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100716_bb0400","article-title":"Results of the Persist-2 phase 3 study of Pacritinib (PAC) versus best available therapy (BAT), including Ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts <100,000\/\u03bcl","volume":"LBA-5","author":"Mascarenhas","year":"2016","journal-title":"Blood."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:38Z","timestamp":1759436618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":80,"alternative-id":["S0268960X20300667"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100716","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of challenging myelofibrosis after JAK inhibitor failure and\/or progression","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100716"}}